Avalo Therapeutics (NASDAQ:AVTX), a clinical-stage biotechnology company focused on developing interleukin-1β (IL-1β)-targeting therapies for immune-mediated inflammatory diseases, reported its financial results for the full year ended December 31, 2025.
Arbutus Biopharma (NASDAQ:ABUS) today reported a landmark set of financial and clinical results for the fourth quarter and full year ended December 31, 2025.
BioLineRx (NASDAQ:BLRX) today announced its audited financial results for the full year ended December 31, 2025, detailing a period of significant fiscal discipline and pipeline maturation.
Bausch + Lomb (NYSE:BLCO) today unveiled positive topline results from its pivotal 24-month U.S. clinical trial of the ELIOS System, an innovative, implant-free procedure designed to treat elevated intraocular pressure (IOP) in patients with open-angle glaucoma.
Viatris (NASDAQ:VTRS) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR (venlafaxine hydrochloride) sustained-release capsules for the treatment of adults with generalized anxiety disorder (GAD).
HUTCHMED (NASDAQ:HCM) announced the initiation of a registrational Phase III clinical trial for HMPL-760, an investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor.
Biogen (NASDAQ:BIIB) and Eisai, today released new real-world findings from a massive U.S. claims analysis demonstrating high long-term persistence rates for patients receiving intravenous (IV) LEQEMBI® (lecanemab).
Nektar Therapeutics (NASDAQ:NKTR) will present Phase 2b clinical data for rezpegaldesleukin at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, the company announced.
Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its proprietary TALEN® gene-editing platform to develop next-generation immunotherapies, announced its financial and operational results for the fiscal year ended December 31, 2025.
Pelthos Therapeutics (NYSE:PTHS) reported its fourth-quarter and full-year 2025 financial results, highlighting a period of rapid commercial acceleration for its flagship product, ZELSUVMI™ (berdazimer gel, 10.3%).
Pfizer (NYSE:PFE) today announced positive topline results from its Phase 3 TALAPRO-3 study, evaluating the combination of TALZENNA® (talazoparib) and XTANDI® (enzalutamide).
Theravance Biopharma (NASDAQ:TBPH) on Thursday reported financial results for the fourth quarter and full year ended December 31, 2025, revealing a year of significant financial recovery tempered by a major strategic pivot.
